ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

Abstract

We conducted a perspective study to investigate whether the expression of excision repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group G (XPG), breast cancer 1 (BRCA1), and ribonucleotide reductase M1 (RRM1) is correlated with clinical outcome of non-small cell lung cancer (NSCLC). Patients with histologically confirmed inoperable stages IIIB and IV NSCLC were collected and followed up until January 2012. Relative cDNA quantification for ERCC1, XPG, BRCA1, and RRM1 was performed using a fluorescence-based, real-time detection method. Cox regression analysis indicated that a high level of ERCC1 was associated with shorter overall survival (OS) and progression-free survival (PFS) times when compared with low expression, with adjusted hazard ratios (HRs) (95% confidence interval (CI)) of 2.25 (1.18-4.39) and 2.63 (1.33-5.25), respectively. High expression of BRCA1 was correlated with shorter OS and PFS times when compared with low expression, and the adjusted HRs (95% CI) were 3.29 (1.72-6.39) and 5.94 (2.80-13.06), respectively. Moreover, we found a significant correlation between BRCA1 expression and age (χ(2) = 4.14, P = 0.04) and stage (χ(2) = 5.26, P = 0.02). Our results suggest that ERCC1 and BRCA1 mRNA expressions are associated with PFS and OS in advanced NSCLC patients treated with platinum-based chemotherapy.

Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

“…Qin et al [17] assessed 116 death cases involving NSCLC using BRCA1 IHC analysis of inoperable stages IIIB and IV and confirmed that patients with high protein expression of BRCA1 were correlated with shorter OS and PFS times, compared to patients with low BRCA1 expression levels. In the present study, survival analysis of 65 death cases of NSCLC demonstrated that patients with negative BRCA1 expression showed longer OS time compared with patients with positive BRCA1 expression (median OS: 34 vs. 21 months, P = 0.011), and their adjusted HRs (95 % CI) for OS were 1.913 (1.161-3.150), respectively.…”

RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report

“…ERCC1 has been widely used for predicting the sensitivity of platinum-based chemotherapy of NSCLC [22,23]. A study by Qin et al [22] also showed that high expression of BRCA1 was correlated with a shorter OS and progression free survival (PFS) compared to low expression.…”

“…ERCC1 has been widely used for predicting the sensitivity of platinum-based chemotherapy of NSCLC [22,23]. A study by Qin et al [22] also showed that high expression of BRCA1 was correlated with a shorter OS and progression free survival (PFS) compared to low expression. Lee et al [24] found that low TS expression was significantly associated with a better response rate (RR) (P=0.037) and a longer PFS (P<0.001) in patients with pulmonary adenocarcinoma who were treated with pemetrexed/cisplatin as first-line chemotherapy.…”

Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer

“…About in vitro studies, resistance to platinum associated with the expression levels of ERCC1 mRNA in ovary (Steffensen et al, 2014), testis (Schettino et al, 2008), bladder and lung cancers (NSCLC) (Qin et al, 2014) were studied and the existence of this relationship in patients with chronic gastric, ovarian, colon, esophagus and NSCLC cancer were confirmed (Schettino et al, 2008).…”